Charles Theuer has more than 20 years of clinical and executive leadership experience. He joined Halozyme as chief medical officer in October 2024 and leads clinical, regulatory affairs, drug safety, and medical affairs.
Dr. Wahl has almost 20 years of pharmaceutical and biotech experience across oncology, gastrointestinal, neurological, infectious, and autoimmune areas. Dr. Wahl is an inventor with more than 150 U.S. and international patents and patent applications.
Darren Snellgrove has more than 30 years of financial leadership experience in the biopharmaceutical and medtech sectors. He joined Halozyme as chief financial officer in June 2026.
Mr. Henderson has nearly 30 years of financial, commercial, and pharmaceutical industry experience. He has been President of JWH Consulting LLC since January 2018 and served as a Healthcare Advisory Director to Berkshire Partners LLC from 2015 to 2019.
Halozyme says patients are central to its work and that its drug delivery technologies and commercial portfolio aim to ease treatment burdens and improve patient outcomes.
